Podcasts about Bellini

Pablo Villegas i Serena Sáenz: Un Diàleg entre Cordes i Veu sota el Cel de MenorcaEl Festival de Música d'Estiu de Ciutadella esdevé aquest any l'epicentre d'una trobada artística excepcional. Pablo Villegas, aclamat ambaixador de la guitarra espanyola, i la soprano de carrera fulgurant Serena Sáenz, uneixen els seus talents en un recital íntim on la música espanyola i la tradició llatinoamericana dialoguen en perfecta harmonia.Un retorn a les arrels i al corPer a tots dos artistes, aquest concert a Menorca no és una parada més a les seves agendes internacionals. Pablo Villegas recorda amb emoció els seus inicis a l'illa, quan amb tot just 17 anys va oferir els seus primers concerts, guardant des de llavors Menorca com un "secret al cor". Per la seva banda, Serena Sáenz sent l'illa com la seva pròpia llar, havent passat llargues temporades des de la seva infància.Aquest vincle personal es trasllada a l'escenari en un format de càmera que Villegas descriu com un binomi ancestral: la veu i la guitarra, "poetes de l'aire" que expliquen històries universals des dels temps dels trobadors.Vulnerabilitat: El camí cap a l'excel·lènciaPablo Villegas ofereix una visió profunda sobre el procés creatiu. Pel guitarrista, la música és el "llenguatge de les emocions" i una eina per construir ponts en una societat enfrontada. El seu objectiu transcendeix la tècnica; busca inspirar i que el públic vegi reflectida a les notes la millor versió de si mateix.Villegas defensa la vulnerabilitat com la clau que obre el cor de l'oient. En tocar, sovint amb els ulls tancats per interioritzar el so, busca alliberar les notes de la “presó” del pentagrama i tornar-les a l'aire en una experiència tridimensional i transformadora. Segons l'artista, cada nota és una oportunitat per a acariciar Déu i crear un espai atemporal on l'artista i el públic es fonen.Un viatge del Bel Canto al BoleroEl programa dissenyat per a aquesta ocasió destaca per la seva sorprenent versatilitat, una qualitat intrínseca a la guitarra, que històricament ha habitat tant a la cort com al carrer. El recorregut musical comença amb el rigor clàssic de Mozart i els arranjaments de Fernando Sor per a Don Giovanni, passant pel bel cant de Bellini.Tot i això, a la segona part, el duo "es deixa anar la cabellera". Serena Sáenz destaca la importància de connectar amb les arrels a través de la música popular, incloent peces de Tàrrega, Granados i una transició cap a l'ànima llatinoamericana amb tangos de Carlos Gardel i boleros immortals com Bésame mucho o El dia que em vulguis.Compromís amb el futurMés enllà dels escenaris, Serena Sáenz demostra el compromís amb la propera generació d'artistes a través del curs Menorca Lírica. En aquest projecte, joves cantants de diversos països (com el Canadà o Alemanya) acudeixen a l'illa per aprofundir en la tècnica vocal i aprendre a navegar el món professional, veient a Serena un referent d'èxit i constància.Aquest recital al Teatre d'Es Born no és només un concert; és una invitació a un viatge emocional, un "buf de vida" on la tècnica i el sentiment es troben per demostrar que, a la música, les diferències es converteixen en punts d'unió.

A cura di Paolo PellegriniVincenzo Bellini, Beatrice di TendaBeatrice di Tenda – Mariana NicolescoAgnese – Stefania ToczyskaFilippo Maria Visconti – Piero CappuccilliOrombello – Vincenzo La ScolaAnichino – Iorio ZennaroRizzardo – Iorio ZennaroDirettore Alberto Zedda – 1986(STU)Orchestra – Orquestre Philharmonique de Monte Carlo

Oper zum Reinbeißen: Nach Bellinis „Norma“ ist sogar ein Pastagericht benannt. Die berühmteste Arie daraus kennt fast jeder – doch „Casta Diva“ ist mehr als schöne Melodie: vokales Krisenmanagement. Von Nick Sternitzke.

To begin the episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the rapidly evolving landscape of wearable insulin delivery, focusing on recent developments in patch pump technology and the growing number of tubeless insulin delivery systems entering the market. The conversation centers on the recent FDA clearance of the Pivot patch pump from Modular Medical, which the hosts describe as an important addition to a field that has historically been dominated by a single tubeless option.Isaacs reviews the design of the Pivot system, explaining that while it is a tubeless insulin pump, it differs from current automated insulin delivery (AID) systems because it does not communicate with a continuous glucose monitor (CGM) or use an insulin-dosing algorithm. Instead, the device delivers programmable basal insulin with ≤2 selectable basal rates and allows users to administer manual bolus doses. The hosts note its 300-unit insulin reservoir, highlighting the larger capacity as a potential advantage for individuals with higher daily insulin requirements.Bellini discusses where Pivot may fit into current clinical practice, suggesting it could provide an option for people who are unwilling or unable to use CGM technology but would still benefit from wearable insulin delivery. She also points to the possibility of future partnerships with commercially available AID algorithms, which could allow the platform to evolve into a more automated system. The hosts acknowledge that current diabetes guidelines generally favor AID for individuals with type 1 diabetes but recognize that simplified technologies continue to have an important role for select patient populations.The discussion expands to the broader pipeline of tubeless insulin pumps currently under development. Isaacs and Bellini review anticipated products from Tandem, Beta Bionics, and Medtronic, noting that virtually every major insulin pump manufacturer is now investing in patch pump technology. They compare reservoir capacities, expected timelines, and device designs while emphasizing the increasing demand for tubeless systems that improve convenience and reduce many of the practical challenges associated with traditional tubing.The hosts also examine several practical design considerations. They discuss Pivot's reusable and disposable components, explaining that many newer patch pumps incorporate reusable elements because of existing intellectual property surrounding fully disposable tubeless systems. While reusable components may lower manufacturing costs, they also introduce considerations such as the potential for patients to misplace components or inadvertently lose them during hospitalizations. Isaacs adds that the simplified design and absence of an onboard algorithm may ultimately make the device more affordable, although real-world pricing remains to be determined.Attention then shifts to recent updates from CeQur Simplicity, which recently announced a 7-day bolus-only patch featuring an expanded 240-unit insulin reservoir and a new one-unit dosing option for individuals requiring smaller mealtime insulin doses. The hosts discuss how these enhancements could broaden the device's applicability while maintaining its emphasis on simplicity, requiring neither smartphone connectivity nor a dedicated mobile application.Bellini highlights the potential synergy between the 7-day patch and emerging once-weekly basal insulin formulations, suggesting that synchronizing weekly basal insulin administration with weekly patch replacement could simplify treatment routines and improve adherence. She emphasizes that insulin therapy should continue to complement guideline-directed pharmacologic management, including GLP-1 receptor agonists, SGLT2 inhibitors, and other glucose-lowering therapies when appropriate.The episode concludes with an optimistic assessment of the future of insulin delivery technology. Isaacs and Bellini emphasize that increasing competition among manufacturers is likely to expand patient choice, improve affordability, and accelerate innovation. They express particular enthusiasm for the continued growth of tubeless insulin delivery, broader pharmacy benefit coverage, and the next generation of AID systems, all of which they believe will further individualize diabetes management and improve outcomes for people requiring insulin therapy.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!To begin the episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss recent advances in type 1 diabetes (T1D) research following presentations at the American Diabetes Association (ADA) Scientific Sessions and the American Association of Clinical Endocrinology (AACE) Annual Meeting. They focus on promising data from an islet cell transplantation study in which all 12 participants achieved insulin independence, with some maintaining normal glycemia for up to 2 years after transplantation.Isaacs explains that the transplanted islet cells restore endogenous insulin production and emphasizes that the study's most notable innovation is its immunosuppression strategy. Rather than relying on calcineurin inhibitors such as tacrolimus, which are associated with significant toxicities, particularly nephrotoxicity, the investigators used the investigational anti-CD40 ligand therapy tegoprubart. The hosts discuss how this approach may improve the long-term safety and feasibility of islet transplantation and note ongoing efforts to develop more convenient formulations beyond the current intravenous infusion administered every 3 weeks.The conversation then turns to the clinical significance of the findings. Bellini highlights that all 12 enrolled participants achieved insulin independence, distinguishing these results from earlier transplantation efforts such as the Edmonton protocol. The hosts also describe the substantial improvements in quality of life reported by participants, including sustained HbA1c values in the normal range without restrictive dietary practices and complete resolution of severe hypoglycemia. Because the trial enrolled individuals with recurrent, life-threatening hypoglycemia, they emphasize that the observed benefits are particularly meaningful for this high-risk population.The hosts also examine several unanswered questions that remain before this approach can become widely available. They discuss the durability of insulin independence, the long-term need for immunosuppressive therapy, treatment costs, and the challenges associated with scaling islet transplantation beyond specialized research centers. Additional findings are reviewed, including the need for repeat transplantation in 2 participants and observations suggesting that individuals with higher body mass index may require greater islet mass to achieve insulin independence. They also discuss the use of tirzepatide in 2 participants, raising questions about the role of insulin resistance and adjunctive therapies following transplantation.Broadening the discussion, Isaacs and Bellini review several emerging strategies aimed at expanding access to curative therapies. These include stem cell-derived islets, large-scale beta cell manufacturing, gene-editing approaches, and encapsulation technologies intended to protect transplanted cells while reducing or eliminating the need for chronic immunosuppression. Drawing on presentations from Aaron Kowalski, PhD, and Laura Jacobsen, MD, they emphasize that despite major advances in continuous glucose monitoring, automated insulin delivery systems, and adjunctive pharmacotherapy, subcutaneous insulin administration remains fundamentally nonphysiologic and cannot fully eliminate long-term complications or disease burden.The episode concludes with a broader discussion of the future of type 1 diabetes research. The hosts highlight efforts to expand eligibility for islet transplantation trials, including studies involving individuals with chronic kidney disease who were previously excluded because of concerns surrounding traditional immunosuppressive therapies. They also underscore the importance of continuing to pursue disease-modifying therapies despite improvements in diabetes technology, emphasizing that glycemic targets alone do not eliminate complications or address disparities in access to care. While acknowledging that a universally applicable cure remains years away, Isaacs and Bellini conclude that the field is making meaningful progress toward safe, durable, and scalable therapies capable of fundamentally changing the treatment of type 1 diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Partimos de un recuerdo a la mezzo y contralto barcelonesa Concepción Callao (1895-1959). La escuchamos en la romanza de Los calabreses de Pablo Luna, el dúo de La Gioconda de Ponchielli con una soprano desconocida y en una parte del diálogo que Carmen mantiene con Don José al final de la ópera junto al tenor Luis Canalda. Luego escuchamos a la soprano ligera María Barrientos en el aria de Susanna de Las bodas de Fígaro de Mozart y en la cabaletta del final de La sonámbula de Bellini. Pasamos a Conchita Supervía para seguirla en Una voce poco fa de El barbero de Sevilla de Rossini y en la Habanera de Carmen de Bizet. Cerramos con otra mezzo: Teresa Berganza, que nos ofrece el aria Cruda sorte de La italiana en Argel de Rossini, Cantares de Turina junto a su marido de entonces, el pianista Félix Lavilla. Con este programa se cierra hasta octubre la temporada de Ars canendi.Escuchar audio

PENSA SE NON CI AVESSI PROVATOALEX BELLINIQuando nel 2004 l'imbarcazione di Alex Bellini naufraga contro gli scogli di Formentera, sembra che il sogno stia per finire. Appena un anno dopo però Bellini riparte. E dopo 226 giorni in mare aperto raggiunge la costa Brasiliana, firmando una delle più straordinarie traversate dell'Oceano Atlantico mai compiute nella storia.  Vent'anni dopo quella incredibile impresa, Alex torna a navigare nei ricordi di quei mesi di fatica, sale e orizzonti infiniti, in un libro che intreccia esplorazione e introspezione, memoria e consapevolezza. “Pensa se non ci avessi provato” non è soltanto il resoconto di un viaggio estremo: è un invito a guardare oltre la paura di fallire e a chiederci quante possibilità ci perdiamo se rinunciamo a provarci.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new real-world data evaluating the Signos platform, an FDA-cleared digital weight-loss solution that combines the Dexcom Stelo continuous glucose monitor (CGM) with artificial intelligence–driven behavioral coaching. The platform delivers personalized recommendations based on glucose responses, dietary intake, physical activity, and user-entered data to support lifestyle modification and weight management.Bellini begins by highlighting the challenges many individuals face in accessing traditional weight-management programs. While in-person and virtual classes can be effective, participation is often limited by time and accessibility. She notes that digital tools such as Signos may offer a scalable alternative by providing continuous support and accountability outside of the clinic setting.The study included adults aged 18 years and older with obesity (BMI >30 kg/m²) who did not have diabetes. Researchers evaluated whether engagement with the platform was associated with weight-loss outcomes, using a metric called “total meaningful actions per day” to measure how frequently participants interacted with the app and its coaching features.Among more than 3,000 participants, periods of active engagement were associated with significantly greater weight loss than periods of low or no engagement. Researchers also evaluated a 180-day cohort of 1,147 participants and found a mean total body weight loss of 5.14% over six months. Participants with higher engagement achieved nearly 6% weight loss, compared with approximately 4.3% among those with lower engagement levels. Bellini emphasizes that these results were achieved without the use of weight-loss medications, underscoring the potential impact of personalized behavioral support combined with CGM data.Isaacs notes that individuals taking anti-obesity medications, including GLP-1 receptor agonists, were excluded from the study. She points out that many patients prefer to pursue weight loss through lifestyle modification rather than long-term pharmacologic therapy, making these findings particularly relevant. At the same time, both hosts suggest that digital coaching platforms could complement GLP-1 therapies by reinforcing nutrition, physical activity, and other healthy behaviors that remain essential for long-term success.The conversation also addresses cost and accessibility. Isaacs notes that while Dexcom Stelo can be purchased independently at a lower monthly cost, access to the full Signos platform requires a higher subscription fee. Although this may be a barrier for some patients, the hosts compare the expense to other commercial weight-management programs and view it as another option within a broader obesity treatment strategy.Throughout the discussion, Isaacs and Bellini emphasize the importance of accountability and ongoing engagement in achieving sustainable weight loss. They highlight the platform's use of AI-generated prompts, reminders, and behavioral challenges designed to keep users engaged and motivated. The episode concludes with optimism about the growing role of digital health technologies in obesity care and the potential for AI-driven, CGM-informed interventions to provide personalized, scalable support for individuals seeking meaningful weight loss.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: Signos. Latest Study Shows Signos Drives Up to 7% Weight Loss Over 6 Months, Rivaling Real-World GLP-1 Weight Loss. BusinessWire. June 23, 2026. Accessed June 23, 2026. https://www.businesswire.com/news/home/20260623955669/en/Latest-Study-Shows-Signos-Drives-Up-to-7-Weight-Loss-Over-6-Months-Rivaling-Real-World-GLP-1-Weight-Loss

Você sabia que a tradição cristã está intimamente ligada ao uniforme da Seleção Brasileira? Em 1950, o Brasil enfrentou um dos maiores traumas de sua história esportiva: o Maracanazo. A derrota para o Uruguai em casa fez com que a tradicional camisa branca fosse vista como "amaldiçoada", forçando uma nação apaixonada pelo futebol a se reinventar. Neste programa, a Brasil Paralelo investiga a fundo a fascinante história por trás das cores que vestem os nossos jogadores. Desde o concurso do Correio da Manhã que deu origem à icônica camisa amarela "Canarinho" desenhada por Aldyr Garcia Schlee, até o momento de desespero logístico na Copa do Mundo de 1958, na Suécia. Descubra como um impasse com a FIFA levou o chefe da delegação, Paulo Machado de Carvalho, a tomar uma decisão de emergência inspirada pelo manto de Nossa Senhora Aparecida. Conheça a jornada de improviso, fé e superação que transformou uma camisa azul comprada às pressas em Estocolmo no símbolo do primeiro título mundial do Brasil, eternizado por lendas como Pelé, Garrincha e Bellini.

We are quickly approaching the third anniversary of the death of Renata Scotto, and that sad commemoration, combined with my desire to produce an episode celebrating Opera Queens, prompted this episode, which features a rare live LP that I once owned a few decades ago and recently returned to my collection. It features live performances of “our diva” from the stage of Carnegie Hall on two different occasions in the mid- to late-1970s: the first, a gala concert on September 12, 1975 with Eve Queler leading the Opera Orchestra of New York on which Scotto performed Rossini (the bravura rondo from Armida) and Donizetti (the mad scene from Anna Bolena). She also sang “Tu che invoco” from Spontini's La Vestale on that concert, and though it was not included on that record, I have unearthed a live recording of that exact performance, which is also included on the episode. The second concert featured on that LP took place on October 31, 1979 under the baton of Lorin Maazel leading the Cleveland Orchestra, and includes a rare performance of Scotto singing from Cherubini's Medea as well as the mad scene from Bellini's Il pirata. In all of these, Scotto is in sterling vocal form, which allows her to fully explore the expressive bel canto possibilities of this music. Since Scotto was also widely accused of being anti-Callas, I also dispute that view with some comments that Scotto made in an interview about Callas's importance as the high priestess of bel canto. I also intone a few more nasty reviews and comments from those who do not hold Scotto in the same high esteem that I (we!) do. For I, too, am one of those opera queens that we are celebrating today. I just happen to have better taste than those that are dissing our diva! Countermelody is the podcast devoted to the glory and the power of the human voice raised in song. Singer and vocal aficionado Daniel Gundlach explores great singers of the past and present focusing in particular on those who are less well-remembered today than they should be. Daniel's lifetime in music as a professional countertenor, pianist, vocal coach, voice teacher, and author yields an exciting array of anecdotes, impressions, and “inside stories.” At Countermelody's core is the celebration of great singers of all stripes, their instruments, and the connection they make to the words they sing. By clicking on the following link (https://linktr.ee/CountermelodyPodcast) you can find the dedicated Countermelody website which contains additional content including artist photos and episode setlists. The link will also take you to Countermelody's Patreon page, where you can pledge your monthly or yearly support at whatever level you can afford.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a series of major pediatric diabetes advancements announced around the American Diabetes Association (ADA) Scientific Sessions 2026, highlighting how recent regulatory decisions are expanding treatment options and improving access to diabetes technologies.The conversation opens with the expanded FDA indication for teplizumab in children and adolescents with newly diagnosed stage 3 type 1 diabetes. Bellini reviews findings from the PROTECT trial, which evaluated teplizumab in patients ages 8 to 17 years within six weeks of diagnosis. She explains that treatment with two 12-day infusion courses resulted in significant preservation of endogenous insulin production, with 95% of participants maintaining peak C-peptide levels above the study threshold at week 78. The hosts discuss the importance of preserving residual beta-cell function, emphasizing its potential role in improving glycemic stability, reducing hypoglycemia risk, and supporting better long-term outcomes for individuals who will live with type 1 diabetes for decades.Isaacs and Bellini explore how this new indication may change the approach to type 1 diabetes screening, particularly among first-degree relatives and individuals at higher risk for autoimmune disease. They note that identifying people in stage 2 type 1 diabetes remains challenging because patients are typically asymptomatic, but the availability of treatment at stage 3 provides clinicians with a new opportunity to intervene soon after diagnosis.The hosts discuss how having an approved therapy may encourage more families to pursue screening and identify additional individuals with early-stage disease. They also address practical considerations, including the importance of starting treatment within the appropriate window, coordinating the two infusion courses, supporting families through treatment logistics, and ensuring access through insurance coverage.The discussion then shifts to the FDA clearance of Dexcom Stelo, the first over-the-counter glucose biosensor cleared for pediatric use in children ages 2 years and older who do not use insulin. Isaacs highlights how this technology could improve access to glucose monitoring for children with prediabetes, type 2 diabetes, or those seeking greater insight into how food, activity, and lifestyle factors influence glucose patterns.The hosts emphasize that expanded access to glucose monitoring could play an important role in helping families make informed decisions about diabetes management. However, they clarify that individuals using insulin require prescription continuous glucose monitoring systems with additional safety features, including hypoglycemia alerts and predictive low glucose notifications.Finally, Isaacs and Bellini discuss the pediatric approval of inhaled insulin as another significant milestone in diabetes care. They review its potential as an alternative to mealtime injections and highlight the opportunity to provide more flexibility for children and families managing type 1 diabetes. The conversation also addresses implementation considerations, including baseline lung function testing, provider familiarity, and adapting clinical workflows to incorporate new treatment approaches.The episode concludes by reflecting on the rapid progress occurring in pediatric diabetes care. With advances in immune-modulating therapies, glucose monitoring technology, and insulin delivery options, the hosts highlight a new era of personalized diabetes management focused on preserving insulin function, improving access, and optimizing outcomes for young people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: Sanofi. Press Release: Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. June 12, 2026. Accessed June 18, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-12-22-09-58-33113492: US Food and Drug Administration. FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children. June 12, 2026. Accessed June 18, 2026. https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children3: Livingston R. FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes. HCPLive. May 29, 2026. Accessed June 18, 2026. https://www.hcplive.com/view/fda-approves-inhaled-insulin-afrezza-pediatric-patients-diabetes

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the latest major trial results like CONNECT, TRIUMPH, and TRANSCEND.To begin the episode, Isaacs and Bellini, discuss major highlights from ADA Scientific Sessions, focusing first on the landmark CONNECT trial evaluating continuous glucose monitoring (CGM) in people with type 2 diabetes who are not treated with insulin. They reflect on the evolution of CGM technology, from its early use primarily in type 1 diabetes to its expanding role in type 2 diabetes management, and explain why this trial represents an important step forward for patients who have historically had limited access to CGM.The hosts review the randomized controlled trial findings, emphasizing the significant improvements in glycemic outcomes, including a 1.6% reduction in A1c from baseline and an approximately 0.9% greater reduction compared with standard care. They also highlight the increase in time in range, with participants using CGM achieving roughly five additional hours per day in target glucose range. The magnitude of these findings is discussed as a practice-changing development, with the potential to influence future clinical guidelines and strengthen recommendations for CGM use among individuals with type 2 diabetes who are not using insulin.The discussion also explores the broader implications of the CONNECT trial for healthcare access and insurance coverage. The hosts note that randomized controlled trial evidence has historically played a key role in shaping standards of care and payer decisions, and they suggest that these results may help support wider adoption of CGM by demonstrating meaningful improvements in glucose control and patient outcomes.The conversation then shifts to emerging pharmacologic advances, with a focus on retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon pathways. The hosts discuss new data showing substantial metabolic benefits in people with type 2 diabetes, including up to 17% weight reduction and nearly 2% A1c lowering. They highlight how these findings represent a major advancement in diabetes and obesity treatment, particularly as clinicians continue to see increasingly powerful effects from next-generation incretin-based therapies.Isaacs and Bellini explore how these therapies may reshape treatment strategies by allowing clinicians to tailor medication choices based on individual patient needs and goals. They discuss the importance of considering both glucose lowering and weight reduction effects, recognizing that some patients may benefit from significant weight loss while others may require a more balanced approach focused primarily on glycemic improvement.The hosts also address important unanswered questions surrounding the use of highly effective weight-loss medications, including appropriate treatment targets, the limitations of BMI as a measure, and the importance of preserving muscle mass and overall function. They emphasize the need to consider body composition, physical activity, resistance training, and patient characteristics—particularly in older adults or those at risk for frailty—when developing long-term treatment plans.The episode concludes with a reflection on the rapidly evolving landscape of diabetes care. The hosts highlight how advances in CGM technology and novel metabolic therapies are creating new opportunities to improve outcomes, personalize treatment approaches, and redefine the future management of people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this special episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in Ner Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Amit Gupta, MBBS, DNB, diabetologist, executive director of the Global Metabolic Health Alliance, and chair of the International Diabetes Federation (IDF) Education Committee, to discuss the state of diabetes care and treatment in India compared to the US.To begin the episode, Gupta introduces the mission of the IDF, highlighting its role as a worldwide federation of scientific societies and patient organizations focused on improving diabetes education, policy, advocacy, and access to care. The conversation explores how diabetes management differs across regions, emphasizing that while the underlying disease mechanisms and available therapies may be similar, access to medications, technologies, healthcare infrastructure, and education varies significantly between countries.Gupta discusses the impact of semaglutide becoming available as a generic therapy in India following patent expiration, describing how reduced costs have improved access to a medication previously limited by affordability barriers. The group considers how increased availability of GLP-1 receptor agonists may transform diabetes and obesity management, while also emphasizing that pharmacologic therapies alone cannot address the global metabolic health crisis. Gupta notes the importance of maintaining focus on long-term lifestyle changes, including nutrition, physical activity, and sustainable weight management, as essential components of comprehensive care.The discussion then shifts to diabetes education and the need for more individualized, patient-centered approaches. Gupta highlights that education must be adapted to regional and cultural contexts, explaining that the challenges faced by a person with diabetes in the United States, Africa, India, or other parts of the world may differ substantially, even though diabetes distress and the burden of daily decision-making are shared experiences. He emphasizes that access to technology, such as continuous glucose monitoring, does not eliminate the need for education and support.Isaacs, Bellini, and Gupta also address the growing challenge of misinformation online and the role of healthcare professionals in helping patients navigate unreliable sources of health information. Gupta explains that clinicians must approach misinformation constructively by providing evidence-based guidance rather than simply dismissing patients' beliefs, reinforcing the importance of translating scientific evidence into practical recommendations that patients can incorporate into their daily lives.The group further examines disparities in the availability of diabetes educators worldwide. Gupta notes that while some regions have established professional pathways for diabetes care and education specialists, many areas lack standardized training, recognition, or policy support to sustain these roles. He stresses that building effective diabetes education systems requires collaboration with policymakers to demonstrate the long-term benefits of structured education programs.The episode concludes with Gupta discussing his work developing a global consensus framework on lifestyle as the foundation of metabolic health. The conversation reinforces that advances in medications and technology must be paired with equitable access, effective education, and sustainable lifestyle interventions to reduce the global burden of diabetes and improve outcomes for people living with metabolic conditions.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Gupta reports disclosures with Lilly, Abbott Diabetes, and the International Diabetes Federation.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Trang Ly, PhD, MBBS, senior vice president and Chief Medical Officer at Insulet, to discuss the continued evolution of automated insulin delivery (AID) technology and emerging developments across the Omnipod platform. To begin the episode, Ly first reviews updates to Omnipod 5, focusing on enhancements aimed at increasing time in automated mode and improving glucose management. She explains that user feedback identified opportunities to support lower glucose targets and reduce interruptions related to system alerts. Data from real-world evidence and computer simulations suggest that lowering the glucose target from 110 to 100 mg/dL may lead to meaningful improvements in time in range and time in tight range without increasing hypoglycemia risk.The group discusses early clinical experience with these enhancements, including findings from users who transitioned to the updated system. Ly highlights that even a highly engaged population already using lower targets experienced additional improvements, including a 2% increase in time in range and a 5% increase in time in tight range over a short period of use. The conversation emphasizes the importance of making these improvements broadly available rather than waiting for routine follow-up visits, particularly given the potential benefits without additional safety concerns.The discussion then turns to Omnipod 6, with Ly sharing newly presented clinical trial data evaluating the next-generation system. She describes the study design, which enrolled users already achieving strong glycemic control on Omnipod 5 and assessed whether further intensification through algorithm improvements could safely provide additional benefits. The results demonstrated a 4% improvement in time in range and up to a 7% increase in time in tight range, with particularly notable improvements among individuals with type 1 diabetes aged 14 years and older.Ly explains that Omnipod 6 builds on previous technology through changes to the core algorithm, allowing the system to deliver more insulin when users do not bolus consistently. The panel explores how this approach may reduce the burden of diabetes management by allowing the algorithm to take on more responsibility while maintaining glycemic control. They discuss the potential psychological benefits of reducing the daily demands placed on people with diabetes, especially as sensor accuracy and automation continue to improve.The conversation also highlights future opportunities for AID in type 2 diabetes. Ly shares early feasibility data from a fully closed-loop system designed specifically for individuals with type 2 diabetes, emphasizing its simplified approach without requiring traditional pump programming or meal bolusing. In this study, participants experienced improvements in time in range, demonstrating the potential for automated insulin delivery to reach broader populations.Isaacs and Bellini discuss the need to reconsider barriers to insulin pump adoption in type 2 diabetes and recognize AID as an accessible option for patients who may benefit. Ly emphasizes that technology should support people across different levels of engagement, offering both highly customizable systems for those seeking intensive management and simpler automated approaches for those looking to reduce daily treatment demands.The episode concludes with a discussion of the future of diabetes technology, including improved connectivity, expanded device flexibility, and continued integration with complementary therapies such as GLP-1 receptor agonists. Ly underscores that innovation should not only improve clinical outcomes but also reduce the burden of care, allowing people with diabetes to spend less time managing their condition and more time living their lives.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Ly reports a disclosure with Insulet.References1: Insulet. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care. June 6, 2026. Accessed June 7, 2026. https://investors.insulet.com/news/news-details/2026/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care/default.aspx

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Ketan Dhatariya, MD, PhD, MS, consultant physician at Norfolk and Norwich University Hospitals, to discuss the evolving landscape of diabetes care, technology access, and clinical implementation. To begin the episode, Dhatariya shares his perspective on the challenges facing diabetologists, including workforce pressures, specialist training, and the difficulty of translating rapidly expanding diabetes guidelines and innovations into everyday clinical practice. The conversation then shifts to the differences between healthcare systems and how those structures influence access to diabetes therapies. Dhatariya discusses the UK's publicly funded healthcare model and the ongoing challenge of balancing the cost of emerging medications and technologies with their long-term benefits. He highlights the importance of demonstrating that investments in diabetes care today can reduce complications and healthcare costs in the future.Dhatariya then reviews the progress of continuous glucose monitoring (CGM) and automated insulin delivery (AID) adoption in the UK. He explains that CGM use among people with type 1 diabetes has become widespread, particularly among children, and that access to closed-loop systems continues to expand through structured implementation plans. He emphasizes the meaningful improvements these technologies have provided, including better glycemic outcomes among children and pregnant individuals, who may experience significant benefits from improved glucose management.The discussion explores how diabetes technology can support people with different lifestyles and challenges, while challenging assumptions about which patients may benefit most from advanced therapies. Dhatariya highlights that CGM and AID can provide valuable support for individuals who may struggle with traditional insulin management, while also emphasizing the need for appropriate education and follow-up to ensure safe and effective use.The group also discusses CGM use in type 2 diabetes and the growing evidence supporting broader access. Dhatariya explains that adoption has been slower because of the larger population affected by type 2 diabetes but notes emerging data suggesting CGM may help reduce complications, hospitalizations, and long-term healthcare costs. He describes the impact of seeing real-time glucose data, explaining how personal experience with CGM can help people better understand the relationship between food, behavior, and glucose patterns.The conversation then turns to access to GLP-1 receptor agonists in the UK and how healthcare systems determine eligibility for newer therapies. Dhatariya discusses the role of national guidance and health economic evaluations in balancing access, affordability, and sustainability. He highlights how improving obesity-related disease management may have broader benefits, including helping reduce the burden of diabetes, cardiovascular disease, and other chronic conditions.The episode also explores inpatient diabetes care and the increasing presence of diabetes technology in hospital settings. Dhatariya discusses guidance developed by the Joint British Diabetes Societies for Inpatient Care to help clinicians safely manage patients admitted while using CGM, insulin pumps, and AID systems. He emphasizes that devices should not automatically be removed and that patients may be able to continue using technology when they are well enough and capable of managing their systems.Finally, Dhatariya discusses the importance of structured diabetes education, including the DAFNE (Dose Adjustment For Normal Eating) program, which teaches carbohydrate counting, insulin adjustment, and self-management skills. He emphasizes that as diabetes technology becomes more advanced, education remains essential for both patients and clinicians. The episode concludes with a discussion of the need for continued advocacy, specialist care, and equitable access to ensure people with diabetes can benefit from ongoing advances in diabetes technology.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Dhatariya reports disclosures with AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded on-site at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Dr. Eugene Wright Jr., MD, the principal of Wright Health Care Solutions and a consulting associate in the department of medicine at Duke University Medical Center, to discuss the development of the ADA scientific statement on diabetes technology implementation in primary care. To begin the episode, Wright reflects on his career as an internist caring for patients with diabetes across diverse settings, including underserved communities where patients often faced significant barriers to accessing care. He describes how his experiences challenged assumptions about which patients would benefit from diabetes technology, noting that many under-resourced patients demonstrated strong engagement and improved self-management when given access to tools such as continuous glucose monitoring (CGM).The discussion focuses on the origins of the ADA scientific statement, which emerged from efforts to identify and overcome barriers limiting the adoption of diabetes technology in primary care. Wright explains that while diabetes technology has demonstrated significant benefits in improving outcomes and patient behaviors, implementation has remained slow in the settings where most people with diabetes receive care. The statement brought together key stakeholders, including clinicians, pharmacists, diabetes care and education specialists, patient representatives, and other experts, to develop practical strategies addressing policy, insurance, workflow, and clinical challenges.Isaacs, Bellini, and Wright explore how CGM can be successfully integrated into primary care by shifting the focus from simply providing access to using data effectively. Wright emphasizes that CGM and ambulatory glucose profile (AGP) reports allow clinicians to transform complex glucose data into actionable insights, helping identify patterns that may not be captured through A1C measurements or traditional glucose monitoring. The group discusses how CGM enables clinicians to ask better questions, uncover barriers to treatment, and engage patients in collaborative conversations without judgment.The hosts highlight the importance of building sustainable workflows, including preparing AGP reports before visits, assigning responsibilities across the care team, and identifying technology champions within practices. Wright explains that successful implementation requires recognizing the unique needs and resources of each primary care setting rather than applying a single model. They discuss the role of telehealth, clinical pharmacists, medical assistants, and other team members in supporting CGM initiation, interpretation, and ongoing management. The conversation also addresses how partnerships with technology manufacturers can simplify onboarding, training, troubleshooting, and patient support.The discussion then expands to insulin pumps and automated insulin delivery systems, with the group noting how advances in technology have reduced complexity and made these therapies more accessible for people with type 2 diabetes. Wright describes how newer systems can help reduce the daily burden of diabetes management by automating adjustments and supporting patients in achieving their goals. The hosts emphasize that diabetes care should move beyond focusing only on glucose metrics and instead consider the lived experience of patients, including the constant decision-making and emotional burden associated with managing diabetes.The episode concludes with a broader call to action for expanding access to diabetes technology across all healthcare settings. Wright emphasizes that many patients do not have access to endocrinology care but still deserve the benefits of modern diabetes tools. The scientific statement represents the beginning of an ongoing effort to improve implementation, strengthen collaboration among stakeholders, and ensure that diabetes technology reaches all patients who can benefit from it.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Wright Jr. reports disclosures with Abbott Diabetes, Bayer AG, Boehringer Ingelheim, Lilly, and Sanofi.ReferencesSection 7: Diabetes technology. Diabetes Obesity and Cardiometabolic CARE. Published online March 23, 2026. doi:10.2337/doc26-a007

01 - Andrewboy & Szecsei feat Kinga Peterfy - Kiskece 2016 (Strong R. Intro Version) 02 - Jamie Woon - Shoulda (Purebeat Special After Remix) 03 - Lee Cabrera & Thomas Gold - Shake It (Move A Little Closer) (Jackwell Remix) 04 - Saby Davis x Eiffel 65 - Return Of The Blue (Jackwell & Szecsei Mashup) 05 - G & G - Personal Jesus (Jackwell & Szecsei Remix) 06 - Rico x Miss Mood - Vihar (Dj Free & Purebeat Remix) 07 - Endor - Pump It Up (TAZI Edit) 08 - Tomcraft - Like A Roller (Jackwell & Field Bootleg) 09 - Radio Slave feat Danton Eeprom - Grindhouse (Johnes & Szecsei 2016 Edit) 10 - Mario - Kimaradás (Darius x Sunshine State Remix) 11 - Gorgon City feat Katy Menditta - Imagination (Jackwell Bootleg) 12 - Diplo feat SIDEPIECE - On My Mind (Jackwell Bootleg) 13 - Gala - Freed from Desire (Orkestrated Re-Rub) 14 - Eminem x Inndrive - Without Me (Jackwell Edit) 15 - Shouse - Won't Forget You (Jackwell Bootleg 2.0) 16 - FISHER - Losing It (Eryk Gee Edit) 17 - Tube & Berger feat Juliet Sikora - Set It Off (Come On Now) (Purebeat Special After Remix 2014) 18 - Offer Nissim feat Maya - First Time (Jackwell & Field Bootleg) 19 - A-Studio feat Polina - S.O.S. 2024 (B-Sensual Mix) 20 - Run DMC vs Jason Nevins - It's Like That (Raxon vs B-Sensual Mix) 21 - Fedde Le Grand & Funkerman feat Dorothy & Andy Sherman - 3 Minutes To Explain (Original Mix) 22 - D. Ramirez & Mark Knight & Underworld - Downpipe (Original Club Mix) 23 - Ron Carroll - Bump To This (Muzzaik Remix) 24 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 25 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 26 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 27 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 28 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 29 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 30 - 50 Cent - In Da Club (RobxDan Extended Remix) 31 - Sebastian Bronk - Everytime We Touch (Extended) 32 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 33 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 34 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 35 - Bassjackers - Around The World (La La La La La) (Extended Mix) 36 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 37 - R3SPAWN & Nia Mousai - Bad Romance (Extended Mix) 38 - Geri Halliwell - It's Raining Men (YuB & MAZZOCCHI Techno Remix) 39 - Sebastian Bronk - L'Amour Toujours (Extended Version) 40 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 41 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 42 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 43 - Martin Books - Liquid (Jackwell Szecsei Edit) 44 - Karen Harding - Say Something (Purebeat Special After Edit) 45 - Andrewboy feat Timi Szegedi - No More Silence (Jackwell & Szecsei Remix) 46 - Strong R. X Szecsei - Érezd A Ritmust (Extended Mix)

Et après on a bu des Bellini en terrasse. Merci à Jaume Balagueró, Nicolas Landais, UFO.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent FDA approval of MannKind's inhaled insulin Afrezza for pediatric patients aged 6 years and older with both type 1 and type 2 diabetes, describing the decision as a major milestone in diabetes therapeutics and the first expansion of the therapy beyond adults. The episode centers on the clinical implications of the approval, the pharmacologic advantages of inhaled insulin, and the practical considerations surrounding implementation in pediatric care settings.The hosts review findings from the INHALE-1 trial, which enrolled 230 pediatric participants aged 4 to 17 years and compared inhaled insulin used alongside basal insulin with standard multiple daily injection (MDI) therapy over 56 weeks. Bellini emphasizes that the study achieved its primary objective of demonstrating glycemic outcomes comparable to traditional insulin regimens, noting that insulin studies are generally designed to establish equivalence rather than superiority. Beyond similar glycemic control, the hosts highlight several clinically meaningful secondary observations, including stable BMI among participants receiving inhaled insulin compared with weight gain in the MDI cohort, increased treatment satisfaction reported by both adolescents and parents of younger children, comparable hypoglycemia rates, and the absence of new safety concerns. Bellini also notes that no decline in lung function was observed among participants using inhaled insulin, despite historical concerns surrounding pulmonary safety with inhaled therapies.A major focus of the discussion is the physiologic pharmacokinetic profile of Afrezza, which Isaacs characterizes as the most physiologic insulin currently available. She explains that inhaled insulin demonstrates measurable activity within approximately 12 minutes, peaks within 35 to 45 minutes, and clears the bloodstream in roughly 90 minutes. The hosts contrast this with subcutaneous rapid-acting insulin analogs, including ultra-rapid formulations, which retain a prolonged “tail” of insulin activity that can increase hypoglycemia risk. Isaacs and Bellini suggest that the shorter duration of inhaled insulin may reduce the cycle of overtreating hypoglycemia and subsequent rebound hyperglycemia, thereby potentially contributing to the absence of weight gain observed in the trial. Bellini further emphasizes that the rapid onset and offset of inhaled insulin restore some of the flexibility and spontaneity often lost in intensive insulin therapy, particularly around meal dosing and correction strategies.The conversation also situates inhaled insulin within the broader framework of individualized diabetes management and the ADA Standards of Care. Isaacs stresses that the approval should not be viewed as competing with automated insulin delivery (AID) systems, but rather as expanding patient choice. The hosts discuss how inhaled insulin may be especially valuable for individuals who do not wish to wear insulin pumps, desire periodic breaks from technology, or want to reduce the burden of injections. Isaacs additionally highlights the growing prevalence of pediatric type 2 diabetes and notes that, despite advances in incretin-based therapies, many youth still require insulin therapy. In that context, the possibility of pairing inhaled mealtime insulin with emerging once-weekly basal insulin formulations and GLP-1 receptor agonists is presented as a potentially transformative strategy for minimizing injection burden.Bellini and Isaacs also address practical implementation challenges within school settings. Because inhaled insulin acts rapidly, Bellini notes that administration timing may need to shift from the nurse's office to the cafeteria environment to avoid hypoglycemia if meals are delayed. At the same time, both hosts recognize that the flexibility of postprandial dosing could offer advantages for children with inconsistent eating patterns or concerns about privacy surrounding insulin administration. They further discuss the utility of inhaled insulin for rapid glucose corrections, noting that additional doses can be administered far sooner than with traditional injected rapid-acting insulin.The episode concludes with discussion of anticipated affordability initiatives from MannKind Corporation, including bridge programs designed to improve early access and reduce financial barriers to therapy. Isaacs and Bellini commend the company's efforts to secure pediatric approval and express optimism that broader availability of inhaled insulin will expand individualized treatment options, improve patient satisfaction, and enhance quality of life for children and adolescents living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: HOLDER

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss several major developments in diabetes technology and obesity therapeutics, beginning with Abbott's announcement that its dual glucose-ketone monitoring systems, Libre Duo and Libre Duo 10 Day, have received CE mark approval in Europe. The hosts describe the devices as the first continuous glucose-ketone monitors capable of simultaneously measuring glucose and ketone levels through a single wearable sensor, with real-time ketone monitoring intended to identify rising risk for diabetic ketoacidosis (DKA). Bellini explains the rationale for separate 15-day adult and 10-day pediatric sensors, noting higher sensor failure rates and greater activity levels in children. Both hosts emphasize the potential clinical significance of continuous ketone monitoring, particularly for individuals with type 1 diabetes (T1D) using insulin pumps, where interruptions in insulin delivery can rapidly precipitate DKA.The discussion further explores how continuous ketone monitoring may expand the safe use of SGLT2 inhibitors in people with T1D and other high-risk populations. Bellini highlights concerns surrounding euglycemic DKA associated with SGLT2 inhibitor therapy and suggests that continuous ketone data could help clinicians identify susceptible individuals earlier, potentially enabling safer and more individualized dosing strategies. Isaacs underscores the limitations of current ketone testing methods, particularly urine ketone testing, which she characterizes as outdated and insufficient for modern diabetes management. The hosts also review additional patient populations that may benefit from continuous ketone monitoring, including individuals with recurrent DKA, pediatric patients with highly variable glycemic patterns, and hospitalized patients at elevated risk for ketosis due to prolonged fasting or treatment interruptions.Isaacs and Bellini also consider practical questions surrounding implementation, including reimbursement, cost, workflow integration, and compatibility with automated insulin delivery systems. They discuss whether continuous ketone monitoring could eventually become standard of care in T1D and debate the broader implications of widespread ketone data availability, including potential consumer interest outside traditional diabetes populations. Both hosts stress the importance of prioritizing access for patients at highest risk for DKA while acknowledging that broader adoption could reshape diabetes monitoring paradigms similarly to the evolution of continuous glucose monitoring.The episode then turns to recent reports involving Dexcom sensors that were reportedly stolen after being removed from the manufacturing process for quality concerns. Bellini explains that some of the affected sensors may not have completed sterility and quality assurance procedures before entering secondary markets. The hosts caution clinicians to review affected lot numbers and encourage ongoing vigilance until additional information becomes available. They also discuss the challenges of communicating recalls and safety alerts directly to patients, particularly for users relying on standalone receivers that may not connect to cloud-based notification systems.Finally, Isaacs and Bellini review newly released topline results from the phase 3 TRIUMPH-1 trial evaluating retatrutide, Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Bellini summarizes findings demonstrating substantial weight reduction among adults with obesity or overweight without diabetes, including mean weight loss exceeding 28% at 80 weeks and continued weight reduction through 104 weeks without evidence of plateau. The hosts note that nearly half of participants achieved at least 30% weight loss, approaching outcomes historically associated with bariatric surgery. They also highlight low discontinuation rates and discuss the implications of future TRIUMPH studies evaluating retatrutide in patients with type 2 diabetes and cardiovascular disease. Isaacs concludes that the emerging data signal a transformative shift in obesity treatment, with pharmacologic therapies increasingly approaching surgical efficacy and potentially reshaping long-term obesity management strategies.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Jeffrey corrobora una filtración y anuncia unos lanzamientos recientes.¿Qué estoy usando hoy?:Mondu Stefanu (M) Parker Penman EmeraldTinteríasAnuncio: Platinum descatalogará la Curidas y la #3776 Century BENU Cocktail Hour (Mojito, Bellini, Pink Lady)Keyno Stationery no. 001 SerenityLAMY Safari Neon Pink y Neon YellowMonteverde Innova 2026 Color of the Year — Cloud DancerSailor 1911 REALO 18kTWSBI Eco Fluorite Purple con BronceTintería del capítulo: COCTELERÍA

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - Sebastian Bronk - L'Amour Toujours (Extended Version) 03 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 04 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 05 - Geri Halliwell - It's Raining Men (YuB & MAZZOCCHI Techno Remix) 06 - Bassjackers - Around The World (La La La La La) (Extended Mix) 07 - SNAP - Rhythm Is A Dancer (LUSSO Bootleg) 08 - Ice Mc - Think About The Way (Kyros Remix) 09 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 10 - Joy Kitikonti x MC Goodgrip - Joyenergizer x Rocking with the Best (LUSSO Mashup Cut) 11 - R3SPAWN - No Good (Extended Mix) 12 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 13 - LMFAO - Sexy & I Know It (Tazi & Beama Edit) 14 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 15 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 16 - Sebastian Bronk - Everytime We Touch (Extended) 17 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 18 - Josh Le Tissier - Calabria (Techno Edit) 19 - Dirty Signal & Blink & Ezra Hazard - No Limit (Extended) 20 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 21 - Barthezz - On The Move (2ACES & Dirty Signal 2026 Edit Cut) 22 - Corona - The Rhythm Of The Night (Cosmic No1ze Techno Remix) 23 - Benny Benassi - Satisfaction (BEAUZ Hard Techno Remix) 24 - Soundlovers - Surrender (ENCR Remix) 25 - Gigi D'Agostino - Bla Bla Bla (Fahjah x Jesyka Nu Groove Remix) 26 - 50 Cent - In Da Club (RobxDan Extended Remix) 27 - La Bouche - Be My Lover (ThnderZ x Lupage x Teddy Cream RaveTok Cut) 28 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg)

01 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Intro Version) 02 - HADEN x Szecsei - Cherokee 2025 (Extended Remix) 03 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 04 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 05 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 06 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 07 - GORDO X Reinier Zonneveld X KAAZE - Loco Loco x Papi (Rudeejay & Da Brozz Bootleg) 08 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 09 - BEAUZ & Cassie Ann - Dame Un Grr (Extended Mix) 10 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 11 - Jaden Bojsen & David Guetta - Let's Go (Scotty Extended Mix) 12 - 50 Cent - In Da Club (RobxDan Extended Remix) 13 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 14 - Travis Scott - FE!N (Rudeejay & Da Brozz Bootleg) 15 - Benny Benassi - Satisfaction (BEAUZ Hard Techno Remix) 16 - BEAUZ - Ocho (Extended Mix) 17 - Dirty Signal & Blink & Ezra Hazard - No Limit (Extended) 18 - Sebastian Bronk - Everytime We Touch (Extended) 19 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 20 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 21 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 22 - Creeds - Push Up (Szecsei & Dante Edit)

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special in-studio episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reflect on major themes and anticipated developments ahead of the upcoming American Diabetes Association (ADA) Scientific Sessions 2026.The discussion opens with Bellini congratulating Isaacs on receiving the ADA Outstanding Educator in Diabetes Award, prompting a conversation centered on Isaacs' forthcoming presentation, “Behind Every Number Is a Story: Transforming Diabetes Care and Education through Technology and Human Connection.” Isaacs reflects on the rapid evolution of diabetes technology over the last decade, from limited continuous glucose monitoring (CGM) access and the emergence of early automated insulin delivery (AID) systems to the integration of artificial intelligence into diabetes care, while emphasizing that successful care remains grounded in human connection and individualized patient experiences.The hosts then preview several therapeutic areas expected to dominate discussion at ADA, particularly the expanding pipeline of incretin-based therapies. Bellini and Isaacs discuss growing excitement surrounding GLP-1, GIP, and glucagon receptor agonists, including anticipated data from triple agonist agents such as retatrutide and emerging oral therapies like orforglipron. They highlight the significance of improved weight-loss efficacy in people with type 2 diabetes (T2D), broader cardiometabolic applications, and the increasing importance of treatment accessibility and affordability. The conversation also explores the expanding role of these therapies in addressing cardiovascular disease, chronic kidney disease, sleep apnea, osteoarthritis, and other obesity-related comorbidities.Technology advancements represent another major focus of the episode. Isaacs and Bellini discuss new CGM-driven insulin titration tools, including Dexcom's Smart Basal feature, designed to address therapeutic inertia among people with T2D using basal insulin. They also examine the growing role of CGM in broader patient populations and discuss evolving ADA recommendations supporting CGM access for any individual likely to benefit from the technology. The hosts express particular enthusiasm for the anticipated arrival of continuous ketone monitoring, including dual glucose-ketone sensors, and consider how these devices may transform diabetic ketoacidosis prevention and patient education, particularly for individuals with type 1 diabetes (T1D).The conversation also highlights continued innovation in insulin delivery systems and connected diabetes devices. Isaacs and Bellini discuss progress toward fully closed-loop AID systems, including ongoing studies evaluating meal-unannounced insulin delivery in T2D. They review emerging insulin pump technologies from Medtronic, including updates to the MiniMed platform and the integration of connected insulin pen systems with real-time CGM data through the MiniMed Go app. The hosts emphasize the importance of preserving therapeutic choice for people who prefer injections over pump therapy or who seek temporary alternatives to wearable devices.Toward the conclusion of the episode, both hosts preview their own ADA presentations. Isaacs discusses an upcoming session on inhaled insulin that will use simulated patient scenarios to explore shared decision-making and individualized therapy selection. Bellini highlights her session focused on skin complications related to diabetes technologies, including allergic reactions and adhesive-related challenges that can interfere with sustained device use. Together, they underscore the importance of addressing practical barriers to technology adoption while continuing to expand therapeutic and technological options for people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Episode: 1573 Donatello: Of his age or for all time?  Today, we ask: Of an age, or of all time?

How could we not check this film out? Collin has welcomed us all – to his wooden ways. Cosimo (Greendale Community College Alum, Luis Guzmán) gets locked up and learns about the perfect heist from his cellmate. He just needs to get out to do it. He confides in his gal pal Rosalind (Patricia Clarkson) which leads to everyone knowing and wanting a piece for themselves. This includes Pero (Sam Rockwell), Riley (William H. Macy), Leon (Isaiah Washington) and Toto (Michael Jeter). This makes Cosimo angry, and he has a lot to say about everyone's mothers. In the background, there's a bit of romance between Pero and Carmela (Jennifer Esposito). Will anyone care? George Clooney is even doing some stuff here. RTS knows when there's a real Bellini on the table. This isn't it. Jeremy considers being a Mullinski but the price has to be just right. La-Mar finds hidden treasures in the cookie jar. Collin has already given you everything. He has welcomed you. Isn't that enough for you? Don't let this turn into a real Kapuchnik. 

A cura di Paolo PellegriniVincenzo Bellini, La SonnambulaAmina (Orfanella), Joan SutherlandElvino (Ricco possidente), Nicolai GeddaIl Conte Rodolfo (Signore del villaggio), Ezio FlagelloLisa (Ostessa), Jeanette ScovottiTeresa (Mugnaia, madre adottiva di Amina), Lili ChookasianAlessio (Contadino), John MacurdyUn Notaio, Andrea VelisCoro e Orchestra del Metropolitan Opera House di New YorkSilvio Varviso, direttore

durée : 02:00:30 - Le 5/7 - par : Mathilde Munos - A 5h45 : Danielle Bellini, retraitée, fondatrice d'un lieu de résidence d'artistes. A 6h20 : Paul Tourret, directeur de l'ISEMAR, l'Institut Supérieur d'Économie Maritime. - réalisation : Elise Amchin, Joachim Taieb Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:05:26 - Le 5/7 - par : Mathilde Munos - Danielle Bellini, retraitée, fondatrice d'un lieu de résidence d'artiste. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:05:26 - Les interviews d'Inter - par : Mathilde Munos - Danielle Bellini, retraitée, fondatrice d'un lieu de résidence d'artiste. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 03 - Dirty Signal & Blink & Ezra Hazard - No Limit (Extended) 04 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 05 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 06 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 07 - R3SPAWN & Nia Mousai - Bad Romance (Extended Mix) 08 - Ice Mc - Think About The Way (Kyros Remix) 09 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 10 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 11 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 12 - 50 Cent - In Da Club (RobxDan Extended Remix) 13 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 14 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 15 - GORDO X Reinier Zonneveld X KAAZE - Loco Loco x Papi (Rudeejay & Da Brozz Bootleg) 16 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 17 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 18 - Sebastian Bronk - Everytime We Touch (Extended) 19 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 20 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 21 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 22 - HUNTRIX - Golden (Wukong & Skyray Mix) 23 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 24 - Sebastian Bronk - L'Amour Toujours (Extended Version) 25 - Bomfunk MC's - Freestyler (Matt Bukovski Cut) 26 - Endor - Pump It Up (SHU Remix Edit) 27 - Strong R. X Szecsei - Érezd A Ritmust (Short Mix) 28 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 29 - Andrewboy & Szecsei feat Kinga Peterfy - Kiskece 2016 (Strong R. Remix)

Adriana Maya sits down with Raissa Bellini for a candid conversation about moving from Italy to Miami, starting over, and building a name fast in adult entertainment and content creation. They get into ambition, attention, online fame, pressure, and what it really takes to grow a brand in a space that moves fast and judges hard. Raissa also opens up about the lifestyle behind the image and the mindset it takes to keep pushing forward.

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 03 - Travis Scott - FE!N (Rudeejay & Da Brozz Bootleg) 04 - BEAUZ & Cassie Ann - Dame Un Grr (Extended Mix) 05 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 06 - Bomfunk MC's - Freestyler (Matt Bukovski Cut) 07 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 08 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 09 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 10 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 11 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 12 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 13 - BLACKPINK - JUMP (Ray Techno Remix) 14 - ROSÉ & Bruno Mars - APT (Scotty Remix) 15 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 16 - Sebastian Bronk - Everytime We Touch (Extended) 17 - Stephanie (HU) - What I've Done (Extended Mix) 18 - ACDC vs Dustin Zahn - Stranger To Thunderstruck (YuB & EDMMARO Techno Mix) 19 - Sebastian Bronk - L'Amour Toujours (Extended Version) 20 - BETON.HOFI & Hundred Sins - Bagira (Strong R. Remix) 21 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 22 - R3SPAWN & Nia Mousai - Bad Romance (Extended Mix) 23 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 24 - Bassjackers - Around The World (La La La La La) (Extended Mix) 25 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 26 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 27 - 50 Cent - In Da Club (RobxDan Extended Remix) 28 - John Summit - Lights Go Out (B00ST x HADEN Extended Remix) 29 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 30 - Gala - Freed from Desire (Kevin Kitchen Bootleg) 31 - Timmy Trumpet x Macklemore - Cant Hold Us x Freaks (Seb Barras Mashup) 32 - DESH & KKevin & Young Fly X Tiesto - Bandana X Free Your Mind (HADEN Mashup) 33 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Hyper Bootleg)

Discothèque Decadence Soundsystem presents DD021: Latin Yacht House Party A sun-drenched voyage through Latin house, yacht grooves, Balearic warmth, and feel-good dancefloor gold. Opening with the smooth luxury of Benny Santiago's “Give Me the Night - Cielo Extended”, the mix glides into The Doobie Brothers' “Long Train Runnin'”, Yacht Rock Revue's “San Junipero”, Daryl Hall & John Oates' “I Can't Go for That” in the Pomo remix, Party Pupils' “Never Too Much”, and Christopher Cross' “Ride Like The Wind - Yacht House Mix” — all bringing that glossy, sunset-on-the-water energy. Then the Latin fire rises. David Penn, DJ Chus & Dr. Kucho!'s “Esperanza” leads into Africanism & Salomão De Bahia's “Cada Vez”, before two personal weapons take centre stage: The Funk Assassin – “Sabor En Tu Piel” and The Funk Assassin – “Di Mi Nombre (Spanglish Pop Soul Edit)”. Both capture the heart of the mix: sensual, rhythmic, warm, and built for that golden-hour moment when the drinks are flowing, the sea is glowing, and the groove takes over. The second half goes full Latin house celebration with Los Amigos Invisibles & Masters At Work, Junior Jack, Basement Jaxx, Negrocan, Ultra Naté, Afro Medusa, Cesária Évora, and Bellini bringing carnival energy, percussion, big hooks, and Balearic heat. Latin house with yacht-house polish. Sunset cocktails. Big grooves. A Discothèque Decadence trip from the crates to the coastline. TRACKLIST 1. Benny Santiago - Give Me the Night Cielo Extended 2. The Doobie Brothers - Long Train Runnin' Full Guitar Mix 3. Platinum City - Rise 4. Lenny Kravitz, RedTop - Low RedTop Extended Remix 5. Yacht Rock Revue - San Junipero Every Night Like Tonight 6. Gaudi, Mr. Mister - Broken Wings Gaudi Rework 7. Daryl Hall & John Oates, Pomo - I Can't Go for That No Can Do Pomo Remix 8. Kenny Summit - Dirty Lowdown 9. That Needs An Edit - Pegged Back Original Mix 10. Party Pupils - Never Too Much 11. Saxity - Forget Me Nots 12. The Spinners - I'll Be Around Simp House Mix 13. Pete Le Freq - Boo Ghee Nites Original Mix 14. Gerry Rafferty, Heleno Vasquez - Baker Street Remix 15. Christopher Cross, Party Pupils - Ride Like the Wind Yacht House Mix 16. DJ Mark Brickman - I Keep Forgetting 17. George Benson, Back2Back - Turn Your Love Around Back2Back Remix 18. David Penn, DJ Chus, Dr. Kucho! - Esperanza Dr. Kucho Remix 19. Africanism, Salomé de Bahia - Cada vez Club Version 20. The Funk Assassin - Sabor En Tu Piel 21. Eric Kupper presents Organika - Malembe Avenida Extended 22. The Funk Assassin - Di Mi Nombre - Spanglish Pop Soul Edit 23. Los Amigos Invisibles, Masters At Work - Aurora Main Mix 24. Junior Jack - Bruja MAW Mix 25. Basement Jaxx, Cassie Watson, David Morales - E Samba Junior Jack Original Club Mix 26. Negrocan - Bingo Bango Latin Bango Mix 2021 Remaster 27. Todd Terry, Gypsymen, Copyright - Cada Vez Denis the Menace Mix 28. Ultra Naté, iitaly, Gregor Salto - Barbarabiri Copyright Remix 29. Daryl Hall & John Oates, Avangart Tabldot - Free Live Your Life iItaly & Gregor Salto Remix 30. Laurent Simeca, Stephan M - Out of Touch Avangart Tabldot Remix 31. Robin Rivera, Rhythm Bangers - Easy Lover 32. Afro Medusa, Knee Deep - Bang Bini & Martini's Exclusive Mix 33. Cesária Evora - Paixão Knee Deep Club Mix 34. Nicola Fasano, Pat Rich - Sangue de Beirona Main Pass By François K. 35. Bellini - 75 Brazil Street Vocal Mix 36. Bellini - Samba de Janeiro Club Mix

durée : 00:59:20 - par : Sébastien Llinares - Entre répertoire italien, français et quelques incursions germaniques, les albums " Consobrinae " d'Hermine Horiot et Giovanni Bellini et "Beyond Vivaldi" d'Evangelina Mascardi avec l'ensemble Estrovagante font un tour d'Europe du répertoire pour luth et théorbe, avec quelques pépites et raretés... - réalisation : Patrick Lérisset, Nelly Portal, Valentin Lévy-Chaudet Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Day Break | Global Tensions, Domestic Power Struggles, and the Fight for America --- 00:00 - Monologue 19:00 – David A. Kallman, Senior Partner at the Kallman Legal Group. Kallman discusses a Minnesota public school proposal involving Muslim prayer rooms. He examines the legal and constitutional questions surrounding religious accommodation in public education. 27:49 – Scott Coburn, Chief Marketing Officer at Patriot Mobile. Coburn highlights Patriot Mobile's connectivity solutions tailored for values-driven and conservative-minded businesses. He explains how the company differentiates itself in the telecom space and directs listeners to patriotmobile.com using code GRUBER. 37:56 - Monologue Featuring Ivey Gruber 46:57 – Robert Bortins, CEO of Classical Conversations and author of Woke and Weaponized. Bortins discusses his book and the influence of ideological shifts in American education. He explains how classical, Christian homeschooling aims to offer an alternative approach. 57:02 – Ally Triolo, RNC Director of Election Integrity. Triolo discusses ongoing election integrity efforts, including developments surrounding redistricting in Virginia. She explains how these issues could impact future elections. 1:05:56 – Arnie Bellini, Chairman of ConnectSecure and technology investor. Bellini discusses the growing importance of AI security and the risks posed by bad actors using artificial intelligence. He emphasizes the need for investment in responsible AI education and infrastructure protection. 1:16:01 - Monologue 1:24:59 – Tom Coulson, owner of Liberty Coin Service. Coulson discusses current trends in precious metals and what investors should be watching. He also reviews listener coin submissions and invites more at https://youtu.be/p757dQjoydM

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 03 - John Summit - Lights Go Out (B00ST x HADEN Extended Remix) 04 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 05 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 06 - Josh Le Tissier - Calabria (Techno Edit) 07 - 50 Cent - In Da Club (RobxDan Extended Remix) 08 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 09 - Jaden Bojsen & David Guetta - Let's Go (Scotty Extended Mix) 10 - Travis Scott - FE!N (Rudeejay & Da Brozz Bootleg) 11 - Sebastian Bronk - Everytime We Touch (Extended) 12 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 13 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 14 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 15 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 16 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 17 - Sebastian Bronk - L'Amour Toujours (Extended Version) 18 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 19 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 20 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 21 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 22 - Endor - Pump It Up (SHU Remix Edit) 23 - Creeds - Push Up (Szecsei & Dante Edit) 24 - BENNETT x Eurythmics - Vois Sur Ton Chemin x Sweet Dreams (Siks Edit) 25 - Gala - Freed from Desire (Kevin Kitchen Bootleg) 26 - Daddy Yankee - Gasolina (YuB x Szecsei Techno Cut) 27 - Swedish House Mafia feat Alicia Keys vs KAAZE feat Alina Pozi - Finally X PAPI (Aurelios & YuB Mashup) 28 - Sean Paul - Temperature (Denero Remix) 29 - Strong R. X Szecsei - Érezd A Ritmust (Extended Mix) 30 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 31 - Strong R. feat Adorján Anna - Kiskece (B00ST Remix)

Gaetano Donizetti was one of Italy's most prolific tunesmiths, with almost 70 operas to his name – about as many as Rossini, Bellini and Verdi all combined - whose arias still cut straight to the heart today. Donald Macleod follows his irresistible rise: from a child brought up in a dark, cramped cellar to become a pioneering master of the style known as bel canto. And like any opera plot, there's triumph and tragedy, headaches and heartbreak…Music featured: L'Elisir d'amore Gloria (from Messa di Gloria) String Quartet No 5 in E minor Waltz in G major Zoraida Amor marinaro L'Esule di Roma Lucrezia Borgia Lucia di Lammermoor String Quartet No 16 Maria Stuarda Messa di Requiem ll sogno “Nostre misere menti” Il sospiro “Donna felice, stanca d'amore” Poliuto La fille du regiment Les Martyrs La fille du regiment Maria Padilla Trovatella “Sovra il campo della vita” Don Pasquale String Quartet No 18 Dom Sebastien: Seul sur la terre Requiem: Offertorio – Lux AeternaProduced by Amelia Parker for BBC Audio Wales and West.For full track listings, including artist and recording details, and to listen to the pieces featured in full (for 30 days after broadcast) head to the series page for Gaetano Donizetti (1797-1848): https://www.bbc.co.uk/programmes/m002sd9nAnd you can delve into the A-Z of all the composers we've featured on Composer of the Week here: http://www.bbc.co.uk/programmes/articles/3cjHdZlXwL7W41XGB77X3S0/composers-a-to-z

A cura di Paolo PellegriniVincenzo Bellini, I PuritaniElvira, Joan Sutherland (soprano)Lord Arturo Talbot, Gianni Raimondi (tenore)Sir Riccardo Forth, Mario Zanasi (baritono)Sir Giorgio, Ferruccio Mazzoli (basso)Enrichetta di Francia, Vera Magrini (mezzosoprano)Lord Gualtiero Valton, Antonio Zerbini (basso)Sir Bruno Robertson, Mario Ferrara (tenore)Coro e Orchestra del Teatro Massimo di PalermoTullio Serafin, direttore

Vasilisa Berzhanskaya Dmitry Korchak Teatro Regio di Parma February 2026 In-house

Sheldon Papp x Chasey LIVE @ Bellini The Cruise by Dj Sheldon Papp

A cura di Paolo PellegriniVincenzo Bellini, NormaNorma, Maria CallasPollione, Mario Del MonacoAdalgisa, Ebe StignaniOroveso, Giuseppe ModestiClotilde, Rina CavallariFlavio, Athos CesariniOrchestra Sinfonica e Coro della RAI di RomaTullio Serafin, direttore

A cura di Paolo PellegriniVincenzo Bellini, La sonnambulaAmina, Joan SutherlandElvino, Nicolai GeddaRodolfo, Giorgio TozziLisa, Jeanette ScovottiTeresa, Gladys KrieseAlessio, Louis SgarroNotaio, Arthur GrahamCoro e Orchestra del Metropolitan Opera di New YorkSilvio Varviso, direttore

Today's Black History Month episode serves also as a belated birthday tribute to the exceptional African American soprano Faye Robinson, who was born in Houston on 2 November 1943. Robinson has a voice that transcends genre, encompassing both lyric-coloratura roles at one end and pure dramatic soprano repertoire on the other. In addition, she has been created vocal works by some of the greatest twentieth-century composers, including Michael Tippett, two of whose major vocal works she premiered, and with whose compositions she is especially associated, and George Walker, whose Lilacs she premiered in 1996 with the Boston Symphony Orchestra, and which subsequently won the 1996 Pulitzer Prize by the judges' unanimous decision. Robinson's immediately recognizable voice presented in a wide-range of repertoire, including the works referenced above and also including arias by Handel, Gounod, Offenbach, Bellini, and Handel, as well as the Chevalier de Saint-Georges; as well as concert work by Schoenberg and Barber. All in all, Faye Robinson's is a voice and artistic presence well worth getting to know better! Happy Belated Birthday, Diva! Countermelody is the podcast devoted to the glory and the power of the human voice raised in song. Singer and vocal aficionado Daniel Gundlach explores great singers of the past and present focusing in particular on those who are less well-remembered today than they should be. Daniel's lifetime in music as a professional countertenor, pianist, vocal coach, voice teacher, and author yields an exciting array of anecdotes, impressions, and “inside stories.” At Countermelody's core is the celebration of great singers of all stripes, their instruments, and the connection they make to the words they sing. By clicking on the following link (https://linktr.ee/CountermelodyPodcast) you can find the dedicated Countermelody website which contains additional content including artist photos and episode setlists. The link will also take you to Countermelody's Patreon page, where you can pledge your monthly or yearly support at whatever level you can afford.

Afro Latino Winter 3 @ DJ Глюк 1. SGX, Dave Ruthwell - Você Vai Vai (Original Mix) 2. Dario Nuñez, Bubba Brothers - Deeper (Original Mix) 3. ARKAD3 - Finder House (Extended Mix) 4. James Hurr, Jay Rah - Pinta La Cara (Extended Mix) 5. Richard Grey & Lissat - Somebody Dance (Funky Tribal Mix) 6. Richard Grey - Show Me Love (Final Afro Mix) 7. Nari - Latinos (Original Mix) 8. All Fred - El Sol (Extended Mix) 9. Bellini, Harald Matthias, Vin Vega - Carnaval (Extended Mix) 10. Gerardo Corona - Zavor (Original Mix) 11. Nausica, Salvatore Papa - Me Rebota (Extended Version) 12. Carlos Agraz - Lokoss (Extended Mix) 13. Erick Cz, Mr Ed (MX) - Meneito (Original Mix) 14. Walter Gardini - Lamor (Original Mix) 15. Funkera - Del Mariachi (Extended Mix)

The Steve Gruber Show | Common Sense Then, ‘Extremism' Now --- 0:00:00 - Hour 1 Monologue 18:55 – Carrie Sheffield, Senior Policy Analyst at the Independent Women's Forum. Sheffield reacts to President Trump's Michigan speech and the defense of his economic strategy. She explains how his message is resonating with voters amid ongoing economic uncertainty. 27:50 – Dr. Alejandro Diaz, Chief of Pediatric Medicine at The Wellness Company. Dr. Diaz discusses RFK Jr.'s efforts to “Make America Healthy Again” and the broader push for medical transparency and patient-first care. Visit twc.health/GRUBER and use promo code GRUBER to save 10%. 38:01 - Hour 2 Monologue 46:40 – Arnie Bellini, cybersecurity CEO and multimillionaire founder of a cybersecurity school. Bellini analyzes escalating deadly protests in Iran and how Chinese technology is being used to launch cyberattacks on Starlink satellites. He explains what this means for global security and U.S. infrastructure. 56:44 – Susan Kokinda, author and organizer with Promethean Action. Kokinda argues that Trump 's visit to the World Economic Forum in Davos isn't about negotiation. Instead, she says he's delivering terms of surrender to global elites. 1:05:41 – Kris Ullman, President of Eagle Forum. Ullman outlines why there should be no flexibility when it comes to taxpayer funding of abortion. She discusses the legal, moral, and fiscal arguments behind Eagle Forum's stance. 1:15:29 - Hour 3 Monologue 1:24:16 – Ron Rademacher, founder of Michigan Back Roads. Rademacher highlights upcoming events and destinations across the state of Michigan. He shares ideas for exploring local history, outdoor adventures, and community gatherings. Visit michiganbackroads.com. 1:34:07 – State Rep. Mark Tisdel, R–Rochester Hills, representing Michigan's 55th District. Rep. Tisdel explains his legislation aimed at keeping cellphones out of classrooms. He discusses how the bill would improve focus, learning, and student well-being. 1:43:01 – Ivey Gruber, President of the Michigan Talk Network. Gruber provides an update from the Supreme Court on efforts to keep men out of women's sports. They discuss the broader legal and cultural implications of the court's actions. --- Visit Steve's website: https://stevegruber.com TikTok: https://www.tiktok.com/@stevegrubershow Truth: https://truthsocial.com/@stevegrubershow Gettr: https://gettr.com/user/stevegruber Facebook: https://www.facebook.com/stevegrubershow Instagram: https://www.instagram.com/stevegrubershow/ Twitter: https://twitter.com/Stevegrubershow Rumble: https://rumble.com/user/TheSteveGruberShow  

Matt and EzRaw announce the 2025 Bellini Award winners.Read the latest news at Brunch BoxingThoughts or questions? Email us at brunchboxingqa@gmail.comHosts: Matt, and EzRawSocial: MikeProducer: Huey

News and Notes- Teofimo Lopez vs. Shakur Stevenson kickoff presser: - Keyshawn Davis pulls up on Richardson Hitchins.- Pitbull Cruz moving on from Lamont Roach.- Devin Haney would like to fight Gervonta Davis in 2026, according to Bill Haney.- Canelo Alvarez will not fight on Cinco de Mayo weekend. He will aim for a September rematch against Terence Crawford.EZ Money Parlay of the Day, EzRaw Report Card, EzRaw Breakdown- EzRaw Breakdown and Report Card: Today's boxing events- Matt's Best Bet.Booking the Territory: Bellini Nominations 2025Quick Hits- The bout between Mike Tyson and Floyd Mayweather will take place in Africa in March, according to Tyson. - Shields To Face Crews-Dezurn In Huge Grudge Match,Read the latest news at Brunch BoxingThoughts or questions? Email us at brunchboxingqa@gmail.comHosts: Matt, and EzRawSocial: MikeProducer: Huey

In this special episode, we're joined once again by two extraordinary figures in the world of opera, mezzo-soprano Frederica von Stade, affectionately known as Flicka, and composer Jake Heggie. Flicka has graced the great opera houses and concert halls for over four decades, known for her captivating performances in roles by Rossini and Bellini, as well as her powerful interpretations of modern works like Heggie's own operas, including Dead Man Walking. Jake is renowned for his operas, having created over ten full-length works, including the widely acclaimed Moby-Dick and, of course, Dead Man Walking.In Part 1, we delve into their creative partnership, particularly focusing on their song cycle Paper Wings, inspired by Flicka's children. They share personal stories about the songs that resonate universally, illustrating how specific experiences can lead to broader emotional connections in art. The discussion also touches on the joy of collaborating and the importance of maintaining humor in their performances.[Subscriber Content] In Part 2, Jake and Flicka reveal more about their personal journeys with music and performance, including the importance of pushing through those dreaded "bad days" where things just don't seem to work right. Flicka discusses the emotional depth in her interpretations, while Jake reflects on the significance of trust in music. Their insights provide a deeper understanding of the art of singing, composing, and music in general enriching the listener's appreciation for the nuances of opera and lyrical storytelling. Listen in for a heartwarming conversation filled with memories, laughter, and profound insights into the world of music and creativity.Would you like more inspirational stories, suggestions, insights, and a place to continue the conversations with other listeners? Visit anthonyplog-on-music.supercast.com to learn more! As a Contributing Listener of "Anthony Plog on Music," you'll have access to extra premium content and benefits including: Extra Audio Content: Only available to Contributing Listeners. Podcast Reflections: Tony's written recaps and thoughts on past interviews, including valuable tips and suggestions for students. Ask Me Anything: Both as written messages and occasional member-only Zoom sessions. The Show's Discord Server: Where conversations about interviews, show suggestions, and questions happen. It's a great place to meet other listeners and chat about all things music! Can I just donate instead of subscribing? Absolutely! Cancel at anytime and easily resubscribe when you want all that extra content again. Learn more about becoming a Contributing Listener @ anthonyplog-on-music.supercast.com!

Dave speaks with Anna Bellini, an alum of the Coaching for Leaders Academy, on how to stop a behavior in order to move forward. Applications to the Coaching for Leaders Academy will open the first week of September. Visit the Academy page to request an early invitation.